Are you evaluating your therapeutics' performance against diet-induced NAFLD/NASH models? Are you in search of a timely preclinical solution that can generate high-quality data for quick go/no-go decision making?
With a global upswing in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with no readily available, FDA-approved therapeutic, many companies have prioritized NAFLD/NASH-related studies in hopes of expediting successful drug launches.
At this event, our expert panel will discuss commercially available in vivo mouse models and their related study design. Specific experimental procedures used to induce the desired disease phenotype will be explained in detail, and an actual case study data will be presented. In addition to in vivo procedures, our panelists will also discuss histological analysis of the liver pathology.